Dynamic modeling of cost-effectiveness of rotavirus vaccination, Kazakhstan

Emerging Infectious Diseases

Volumn 20, Issue 1, 2014, Pages 29-37

  de Blasio, Birgitte Freiesleben ^a,b   Flem, Elmira ^a   Latipov, Renat ^c   Kuatbaeva, Ajnagul ^d   Kristiansen, Ivar Sønbø ^b  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Institute of Virology   (Uzbekistan)

^d Scientific Practical Centre of Epidemiologic Surveillance   (Kazakhstan)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; ROTAVIRUS VACCINE;

ACUTE DIARRHEA; ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; GASTROENTERITIS; HEALTH CARE COST; HOSPITALIZATION; HUMAN; IMMUNIZATION; INCOME; MORTALITY; PRESCHOOL CHILD; SENSITIVITY ANALYSIS; VIRUS TRANSMISSION;

BREAK-EVEN PRICE; COST-EFFECTIVENESS; DYNAMIC MODELING; HERD IMMUNITY; KAZAKHSTAN; ROTAVIRUS; VACCINATION; VACCINE; VIRUSES;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INFANT; INFANT, NEWBORN; KAZAKHSTAN; MIDDLE AGED; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION; YOUNG ADULT;

EID: 84890944545     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2001.130019     Document Type: Article

References (39)

1. Centers for Disease Control and Prevention. Rotavirus surveillance-worldwide, 2009. MMWR Morb Mortal Wkly Rep. 2011; 60:514-6.
2. Desai R, Oliveira LH, Parashar UD, Lopman B, Tate JE, Patel MM. Reduction in morbidity and mortality from childhood diarrhoeal disease after species A rotavirus vaccine introduction in Latin America: a review. Mem Inst Oswaldo Cruz. 2011;106:907-11.
3. Tate JE, Cortese MM, Payne DC, Curns AT, Yen C, Esposito DH, et al. Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data. Pediatr Infect Dis J. 2011;30:S56-60. http://dx.doi.org/10.1097/INF. 0b013e3181fefdc0
4. Buttery JP, Lambert SB, Grimwood K, Nissen MD, Field EJ, Macartney KK, et al. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. Pediatr Infect Dis J. 2011;30:S25-9. http://dx.doi.org/10.1097/ INF.0b013e3181fefdee
5. Latipov R, Utegenova E, Kuatbayeva A, Kasymbekova K, Abdykarimov S, Juraev R, et al. Epidemiology and burden of rotavirus disease in Central Asia. Int J Infect Dis. 2011;15:e464-9. http://dx.doi.org/10.1016/j.ijid.2011.03.014
6. Population Division of the Department of Economic and Social Affairs of theUnited Nations Secretar. World Population Prospects: The 2010 Revision. 2012. [cited 2012 Dec 1]. http://esa.un.org/ undp/wpp/index.html
7. World dataBank. World Development Indicators and Global Development Finance. 2012. [cited 2012 Nov 25]. http://databank.worldbank. org/ddp/home.do
8. Latipov R, Kuatbaeva A, Kristiansen O, Aubakirova S, Akhanaeva U, Kristiansen IS, et al. Economic burden of rotavirus disease in children under 5 years in Kazakhstan. Vaccine. 2011;29:4175-80. http://dx.doi.org/10.1016/j.vaccine.2011.03.019
9. Flem ET, Latipov R, Nurmatov ZS, Xue Y, Kasymbekova KT, Rheingans RD. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan. J Infect Dis. 2009;200(Suppl 1):S195-202. http://dx.doi.org/10.1086/605040
10. Isakbaeva ET, Musabaev E, Antil L, Rheingans R, Juraev R, Glass RI, et al. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine. 2007;25:373-80. http://dx.doi.org/10.1016/ j.vaccine.2006.07.029
11. Shim E, Galvani AP. Impact of transmission dynamics on the costeffectiveness of rotavirus vaccination. Vaccine. 2009;27:4025-30. http://dx.doi.org/10.1016/j.vaccine.2009.04.030
12. Atkins KE, Shim E, Carroll S, Quilici S, Galvani AP. The costeffectiveness of pentavalent rotavirus vaccination in England and Wales. Vaccine. 2012;30: 6766-76.
13. Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI. Oral rotavirus vaccines: how well will they work where they are needed most? J Infect Dis. 2009;200(Suppl 1):S39-48. http://dx.doi. org/10.1086/605035
14. de Blasio BF, Kasymbekova K, Flem E. Dynamic model of rotavirus transmission and the impact of rotavirus vaccination in Kyrgyzstan. Vaccine. 2010;28:7923-32. http://dx.doi.org/10.1016/ j.vaccine.2010.09.070
15. Pitzer VE, Atkins KE, de Blasio BF, Van ET, Atchison CJ, Harris JP, et al. Direct and indirect effects of rotavirus vaccination: comparing predictions from transmission dynamic models. PLoS ONE. 2012;7:e42320. http://dx.doi.org/10.1371/journal.pone.0042320
16. United Nations Population Divison Home page [cited 2012 Oct 1]. http://www.un.org/esa/population/
17. Agency of the Republic of Kazakhstan [cited 2012 Oct 1]. http://www.eng.stat.kz
18. United Nations Children's Fund (UNICEF), Agency of the Republic of Kazakhstan on Statistic. Kazakhstan Multiple Indicator Cluster Survey 2006. 2007 [cited 2012 Dec 5]. http://www.childinfo.org/ files/MICS3_Kazakhstan_FinalReport_2006_Eng.pdf
19. Kapikian AZ, Wyatt RG, Levine MM, Yolken RH, VanKirk DH, Dolin R, et al. Oral administration of human rotavirus to volunteers: induction of illness and correlates of resistance. J Infect Dis. 1983;147:95-106. http://dx.doi.org/10.1093/infdis/147.1.95
20. White LJ, Buttery J, Cooper B, Nokes DJ, Medley GF. Rotavirus within day care centres in Oxfordshire, UK: characterization of partial immunity. J R Soc Interface. 2008;5:1481-90. http://dx.doi. org/10.1098/rsif.2008.0115
21. Ward RL, Bernstein DI, Young EC, Sherwood JR, Knowlton DR, Schiff GM. Human rotavirus studies in volunteers: determination of infectious dose and serological response to infection. J Infect Dis. 1986;154:871-80. http://dx.doi.org/10.1093/infdis/154.5.871
22. Ward RL, Bernstein DI, Shukla R, McNeal MM, Sherwood JR, Young EC, et al. Protection of adults rechallenged with a human rotavirus. J Infect Dis. 1990;161:440-5. http://dx.doi.org/10.1093/infdis/161.3.440
23. Velázquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, Carter-Campbell S, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med. 1996;335:1022-8. http://dx.doi.org/10.1056/NEJM199610033351404
24. Mäkelä M, Marttila J, Simell O, Ilonen J. Rotavirus-specific T-cell responses in young prospectively followed-up children. Clin Exp Immunol. 2004;137:173-8. http://dx.doi.org/10.1111/ j.1365-2249.2004.02509.x
25. Vesikari T, Karvonen A, Korhonen T, Espo M, Lebacq E, Forster J, et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine. 2004;22:2836-42. http://dx.doi.org/10.1016/ j.vaccine.2004.01.044
26. Braeckman T, Van HK, Meyer N, Pircon JY, Soriano-Gabarro M, Heylen E, et al. Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study. BMJ. 2012;345:e4752. http://dx.doi.org/10.1136/bmj.e4752
27. Justino MC, Linhares AC, Lanzieri TM, Miranda Y, Mascarenhas JD, Abreu E, et al. Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belem, Brazil. Pediatr Infect Dis J. 2011;30:396-401. http://dx.doi.org/10.1097/ INF.0b013e3182055cc2
28. Yen C, Figueroa JR, Uribe ES, Carmen-Hernandez LD, Tate JE, Parashar UD, et al. Monovalent rotavirus vaccine provides protection against an emerging fully heterotypic G9P[4] rotavirus strain in Mexico. J Infect Dis. 2011;204:783-6. http://dx.doi. org/10.1093/infdis/jir390
29. Vainio K. Rotavirus genotype distribution in Kyrgyzstan and Kazakhstan, 2007-2009. APMIS. 2013;121(5):447-55. http://dx. doi.org/10.1111/apm.12014
30. Patel M, Pedreira C, De Oliveira LH, Umana J, Tate J, Lopman B, et al. Duration of protection of pentavalent rotavirus vaccination in Nicaragua. Pediatrics. 2012;130:e365-72. http://dx.doi.org/10.1542/ peds.2011-3478
31. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376:606-14. http://dx.doi.org/10.1016/S0140-6736(10)60889-6
32. Cortese MM, Immergluck LC, Held M, Jain S, Chan T, Grizas AP, et al. Effectiveness of monovalent and pentavalent rotavirus vaccine. Pediatrics. 2013;132:e25-33. http://dx.doi.org/10.1542/peds.2012-3804
33. Staat MA, Payne DC, Donauer S, Weinberg GA, Edwards KM, Szilagyi PG, et al. Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics. 2011;128:e267-75. http://dx.doi. org/10.1542/peds.2010-3722
34. Akmatov MK, Kretzschmar M, Kramer A, Mikolajczyk RT. Determinants of childhood vaccination coverage in Kazakhstan in a period of societal change: implications for vaccination policies. Vaccine. 2007;25:1756-63. http://dx.doi.org/10.1016/j. vaccine.2006.11.030
35. World Health Organization. World Health Assembly Expanded Programme on Immunization. [cited 2013 Nov 14]. http://www. who.int/immunization_delivery/en/
36. Fischer TK, Anh DD, Antil L, Cat ND, Kilgore PE, Thiem VD, et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis. 2005;192:1720-6. http://dx.doi.org/10.1086/497339
37. Podewils LJ, Antil L, Hummelman E, Bresee J, Parashar UD, Rheingans R. Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis. 2005;192(Suppl 1):S133-45. http://dx.doi.org/10.1086/431513
38. Atkins KE, Shim E, Pitzer VE, Galvani AP. Impact of rotavirus vaccination on epidemiological dynamics in England and Wales. Vaccine. 2012;30:552-64. http://dx.doi.org/10.1016/j.vaccine. 2011.11.064
39. Vesikari T, Karvonen A, Ferrante SA, Ciarlet M. Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. Eur J Pediatr. 2010;169:1379-86. http://dx.doi.org/10.1007/s00431-010-1242-3